CA3008195A1 - Treatment of intrahepatic cholestasis and related liver diseases - Google Patents

Treatment of intrahepatic cholestasis and related liver diseases Download PDF

Info

Publication number
CA3008195A1
CA3008195A1 CA3008195A CA3008195A CA3008195A1 CA 3008195 A1 CA3008195 A1 CA 3008195A1 CA 3008195 A CA3008195 A CA 3008195A CA 3008195 A CA3008195 A CA 3008195A CA 3008195 A1 CA3008195 A1 CA 3008195A1
Authority
CA
Canada
Prior art keywords
composition
activity
atcc
strain
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3008195A
Other languages
English (en)
French (fr)
Inventor
Fredrik Karlsson
Bo Mollstam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabogen AB
Original Assignee
Metabogen AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabogen AB filed Critical Metabogen AB
Publication of CA3008195A1 publication Critical patent/CA3008195A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3008195A 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases Pending CA3008195A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266771P 2015-12-14 2015-12-14
US62/266,771 2015-12-14
PCT/EP2016/080941 WO2017102816A1 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Publications (1)

Publication Number Publication Date
CA3008195A1 true CA3008195A1 (en) 2017-06-22

Family

ID=57570064

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3008195A Pending CA3008195A1 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Country Status (16)

Country Link
US (1) US20180369297A1 (https=)
EP (1) EP3389680B1 (https=)
JP (2) JP2018537484A (https=)
KR (1) KR20180094950A (https=)
CN (1) CN109069548A (https=)
AU (1) AU2016374365B2 (https=)
BR (1) BR112018012022A2 (https=)
CA (1) CA3008195A1 (https=)
CL (1) CL2018001548A1 (https=)
ES (1) ES2962302T3 (https=)
IL (1) IL259480B2 (https=)
MX (1) MX2018007227A (https=)
RU (1) RU2743405C2 (https=)
SG (1) SG11201804255QA (https=)
WO (1) WO2017102816A1 (https=)
ZA (1) ZA201804660B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
CN112280720B (zh) * 2020-11-19 2021-07-13 山东龙昌动物保健品有限公司 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用
US20240122996A1 (en) * 2021-02-08 2024-04-18 Liscure Biosciences Co., Ltd. Pharmaceutical composition for preventing or treating cholestatic liver injury comprising leuconostoc citreum strain as active ingredient
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
GB2628547A (en) * 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
AU4905300A (en) * 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2381211T3 (es) * 2006-02-15 2012-05-24 Nestec S.A. Uso del Bifidobacterium longum para prevenir y tratar inflamaciones
US20120128633A1 (en) * 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒
CA2926466C (en) * 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof

Also Published As

Publication number Publication date
RU2018124487A3 (https=) 2020-05-29
KR20180094950A (ko) 2018-08-24
CL2018001548A1 (es) 2018-07-20
RU2743405C2 (ru) 2021-02-18
MX2018007227A (es) 2018-08-01
ES2962302T3 (es) 2024-03-18
JP2018537484A (ja) 2018-12-20
BR112018012022A2 (pt) 2018-12-04
IL259480A (en) 2018-07-31
JP2022166039A (ja) 2022-11-01
WO2017102816A1 (en) 2017-06-22
US20180369297A1 (en) 2018-12-27
RU2018124487A (ru) 2020-01-10
IL259480B1 (en) 2023-05-01
SG11201804255QA (en) 2018-06-28
AU2016374365B2 (en) 2023-04-13
CN109069548A (zh) 2018-12-21
AU2016374365A1 (en) 2018-07-12
IL259480B2 (en) 2023-09-01
ZA201804660B (en) 2022-12-21
EP3389680C0 (en) 2023-10-11
EP3389680A1 (en) 2018-10-24
EP3389680B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
AU2016374365B2 (en) Treatment of intrahepatic cholestasis and related liver diseases
Baothman et al. The role of gut microbiota in the development of obesity and diabetes
Ahmadi et al. The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial
Nieuwdorp et al. Role of the microbiome in energy regulation and metabolism
Gorbach Estrogens, breast cancer, and intestinal flora
Babiker et al. Metabolic effect of gum Arabic (Acacia Senegal) in patients with type 2 diabetes mellitus (T2DM): randomized, placebo controlled double blind trial
JP2013542195A5 (https=)
US20220378809A1 (en) Synthetic composition for balancing the bile acid profile in the intestine
Chen et al. Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support
CN102014960A (zh) 基于护肝剂和益生元的药物组合物、其制备及其应用
Zhang et al. Microbial bile acid metabolite ameliorates mycophenolate mofetil-induced gastrointestinal toxicity through vitamin D3 receptor
Frezza et al. Prevention by S-adenosylmethionine of estrogen-induced hepatobiliary toxicity in susceptible women.
HK40002061A (en) Treatment of intrahepatic cholestasis and related liver diseases
RU2318538C1 (ru) Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение
FALOON Metabolic effects of nonabsorbable antibacterial agents
Floreani et al. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis
EP1437140B1 (en) Oral pharmaceutical formulation containing active carbon and use of the same
US10398717B2 (en) Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
Parekh et al. The Role of Gut Microflora in Obesity-Does the Data Provide an Option for Intervention?
Hassan et al. Development of bile acid biogenesis in the rat: effect of neonatal thyroidectomy, adrenalectomy, and streptozotocin-induced diabetes
Orlic et al. Fetal rat utilization of 55Fe absorbed by fetal intestine from swallowed amniotic fluid
ITMI971372A1 (it) Medicamento utile per ridurre la massa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella seconda
Ventura et al. A double-blind controlled trial of the efficacy and safety of taurohyodeoxycholic acid in the treatment of dyspeptic disturbances associated with gallstones or other hepatic disorders
Sauter et al. Effect of dietary fiber on serum bile acids in patients with chronic cholestatic liver disease under ursodeoxycholic acid therapy
US3446895A (en) Methods for treating muscular dystrophy with a 1-methyl-delta**1-androsten-17beta-ol-3-one and digitoxin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211126